Abstract:Introduction Negative symptoms are a key aspect of schizophrenia, significantly impacting a patient's functioning and quality of life. These symptoms are deemed predominant when they dominate the clinical picture and positive symptoms are only minimally present. As articulated in the most recent guidance by the European Psychiatric Association, including self-report measures is encouraged in negative symptom studies as they can further complement the observer-rated scales when assessing negative symptoms of schizophrenia. Objectives The objective of the poster is to compare the views of patients vs. doctors regarding predominant negative symptoms during a 1-year observational study. Methods This was a 1-year-long, prospective, multicentric cohort study with three visits after baseline at 3, 6 and 12 months. Adult outpatients with a schizophrenia diagnosis according to the International Classification of Diseases 10th edition who exhibited predominant negative symptoms according to clinical judgement were included. Patients received pharmacological and some non-pharmacological treatment as usual. The primary outcome measure was the modified Short Assessment of Negative Domains (m-SAND), an anamnesis-based scale that is composed of 7 items: two positive items (delusions and hallucinations) which make the m-SAND Positive sub-scale (m-SAND-P) and five negative items (anhedonia, alogia, avolition, asociality and affective flattening) which make the m-SAND Negative sub-scale (m-SAND-N) Each item is rated from 0 to 5 (not observed; mild; moderate; moderately severe; severe; and extreme). Other measurements included the Self-evaluation of Negative Symptoms (SNS), a validated scale that provides meaningful information regarding the patients' own perception of their negative symptoms. Least squares (LS) means were calculated for the change from baseline to final visit using a mixed model for repeated measures (MMRM). Results 188 patients were included in the study. The mean age was 39.8 years and 65% of patients were men. The mean duration of illness was 12 years. At baseline, patients rated alogia and apathy (mean SNS score: 5.7) to be the most severe and then asociality (5.5). In contrast, doctors found affective blunting (mean m-SAND total score: 4.3), apathy (4.2) and anhedonia (4.0) to be the most severe. After the end of the observational period all negative symptom sub-domains improved significantly according to both the patients' and doctors' views. The latter group reported -1.9 LS mean change from baseline in apathy, -1.8 in anhedonia, and -1.7 in asociality (all p-value <0.0001). Patients felt most change in alogia and asociality (-2.7), and apathy and anhedonia (-2.4). Conclusions In summary, both patients and doctors reported significant improvement in predominant negative symptoms. Nonetheless, there were some differences how they perceived severity and change in the specific domains. Disclosure of Interest J. Dragasek: None Declared, Z. Dombi Employee of: Gedeon Richter Plc., K. Acsai: None Declared, V. Dzurilla Employee of: Gedeon Richter Plc., Á. Barabássy Employee of: Gedeon Richter Plc.

Analysis of Relevant Factors Affecting the Treatment of the Negative and Positive Symptoms in Schizophrenics.

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Gender Differences of Schizophrenia Patients with and Without Depressive Symptoms in Clinical Characteristics.

Association Between Symptom Control and Functional Improvement in Patients with Acute Schizophrenia: A Post Hoc Analysis of an Open-Label, Single-Arm, Multi-Center Study of Paliperidone-Extended Release Formulation.

Effects of drug attitudes on treatment compliance and psychiatric symptoms of schizophrenia: an one year follow-up study

Clinical Study of Psychological Intervention Combined with Antipsychotics for Schizophrenia

Psychotic Symptoms and Attitudes Toward Medication Mediate the Effect of Insight on Personal-Social Functions in Patients with Schizophrenia: One-Year Randomized Controlled Trial and Follow-Up

Sex Differences in Pharmacotherapy of Schizophrenia:Findings from National Survey 2012 on Use of Psychotropic Medications

Relationship Between Curative Effect and Serum Inflammatory Factors Level in Male Patients With First-Episode Schizophrenia Treated With Olanzapine

Predominant negative symptoms: views of patients vs. doctors in a 1-year observational study

Pharmacogenetics of Treatment in First-Episode Schizophrenia: D3 and 5-HT2C Receptor Polymorphisms Separately Associate with Positive and Negative Symptom Response

Relationship Between Cognitive Deficits and Negative Symptoms in Patients With Schizophrenia

Initial attitudes toward a drug predict medication adherence in first-episode patients with schizophrenia: a 1-year prospective study in China

Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders

Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis

Impact of negative signs on therapeutic compliance in patients with schizophrenia

The neuroendocrine response to paroxetine challenge, immune indices, free radical metabolism and antipsychotic treatment in schizophrenia

Factors Related to the Length of Stay for Patients With Schizophrenia: A Retrospective Study

Analysis of Medication Adherence and Its Influencing Factors in Patients with Schizophrenia in the Chinese Institutional Environment

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics.

A real-world data analysis of electronic health records to investigate the associations of predominant negative symptoms with healthcare resource utilisation, costs and treatment patterns among patients with schizophrenia